Table of Contents
The spanish Agency for Medicines and Health Products (AEMPS) will soon begin preparing therapeutic Positioning Reports (IPT) for medicines receiving a positive evaluation from the European Medicines Agency (EMA). This process impacts both newly approved drugs and those with new indications or modifications, as outlined in a recent proclamation.
Understanding Therapeutic Positioning Reports (IPT)
Therapeutic Positioning Reports provide an assessment of a medicine’s place within the Spanish healthcare system. These reports are critical for informing clinical practice guidelines, health technology assessments, and pricing and reimbursement decisions. They ensure that new medicines are appropriately integrated into the existing treatment landscape,maximizing patient benefit and optimizing healthcare resource allocation.
Process for New Medicines
For new medications,the AEMPS will initiate the IPT process once it receives notification from the marketing Authorization Holder (TAC) of their intention to market the drug in spain,along with a request for a national code. This notification is crucial; without it, the AEMPS will not begin preparing the corresponding IPT [[1]]. Marketing Authorization Holders must submit this information through the RaefarII submission.
Process for New Indications or Modifications
The process differs slightly for new indications or modifications to existing drugs. In these cases, the AEMPS will automatically begin preparing the IPT without requiring prior notification from the TAC. This streamlined approach simplifies the process for updates to already-approved medications.
Role of the EMA and CHMP
The AEMPS process is directly linked to the evaluations conducted by the EMA’s Committee for Medicinal Products for Human Use (CHMP). The AEMPS focuses on therapeutic positioning after a positive CHMP opinion has been reached. This ensures alignment with the broader European regulatory framework and facilitates timely access to innovative therapies for Spanish patients.
AEMPS Oversight and spain’s Regulatory Landscape
While Spain adheres to EU GMP guidelines, the AEMPS holds meaningful obligation for national-level oversight. This includes new drug applications, clinical trials, enforcement of regulations, and the implementation of additional Spanish requirements [[1]]. the AEMPS also provides a wealth of information regarding medicines for human use, including drug information centers and pharmacovigilance data [[3]].
Looking ahead
The AEMPS’s proactive approach to therapeutic positioning reports demonstrates it’s commitment to ensuring the safe, effective, and appropriate use of medicines within Spain. By carefully evaluating the role of new therapies, the agency aims to optimize healthcare outcomes and provide the best possible care for Spanish citizens. This initiative aligns with ongoing efforts to enhance the efficiency and openness of the Spanish pharmaceutical regulatory landscape.
Publication Date: 2026/01/08 19:40:14